# Butterfly Reports FDA Clearance for Blind-Sweep Gestational-Age AI

Times of AI Desk · 2026-03-30 · Enterprise

[https://timesof.ai/2026/03/butterfly-network-ultrasound-ai-tool-fda-clearance](https://timesof.ai/2026/03/butterfly-network-ultrasound-ai-tool-fda-clearance)

> Butterfly Network reported FDA clearance for its automated Gestational Age ultrasound tool, which it calls the first cleared blind-sweep AI for pregnancy dating. The company reports training on 21M+ images and equivalence to sonographer biometry at 16–37 weeks; clearance is not an outcomes trial.

Prenatal dating usually needs a trained sonographer. Butterfly’s proprietary frame is **FDA clearance for a blind-sweep AI** that claims biometry-equivalent gestational age from a guided handheld sweep — access story first, clinical outcomes still to prove at scale.

**Butterfly Network** (March 30) received FDA clearance for a fully automated **Gestational Age (GA) Tool** on its handheld ultrasound. The company describes it as first FDA-cleared blind-sweep ultrasound AI for estimating gestational age. Workflow: enter fundal height, apply gel, perform guided sweeps — results in **under two minutes**, with use by healthcare practitioners; the company says tutorials do not replace professional clinician training. Deep-learning models developed with the **University of North Carolina at Chapel Hill**; trained on **more than 21 million** images across diverse demographics. Performance claimed **equivalent to standard biometry** for patients **16–37 weeks** gestation.

Already deployed in **Malawi** and **Uganda** with **Gates Foundation** grant support. Clearance opens broader U.S. rural and Sub-Saharan rollout. Sachita Shah, MD (VP Global Health): maternal imaging access as urgent priority; Steve Cashman (CBO) flags emergency, high-mortality, and rural U.S. use cases.

## Claims vs checks

Clearance and product description are **Butterfly primary** (press release). Equivalence to sonographer biometry is company/clinical claim tied to the clearance package — not an independent Times of AI audit. The release describes grant-backed deployments, but does not present a population-outcome randomized trial.

## Limits

- FDA clearance ≠ proven maternal/fetal mortality reduction.
- Performance band is 16–37 weeks; outside that window is out of scope here.
- Handheld + AI still needs power, gel, and workflow adoption.

**Correction (October 14, 2026):** Made company attribution explicit and clarified that clinician training remains necessary; the release does not establish mortality benefits.

## Sources

- [Butterfly Network: FDA-cleared Gestational Age Tool (March 30, 2026)](https://www.butterflynetwork.com/press-releases/fda-cleared-gestational-age-tool)